Thrivent Financial for Lutherans
AKBA icon

Thrivent Financial for Lutherans’s Akebia Therapeutics AKBA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-115,718
Closed -$324K – 2523
2020
Q4 		$324K Hold
115,718
– – ﹤0.01% 2276
2020
Q3 		$290K Buy
115,718
+59,264
+105% +$520K ﹤0.01% 2193
2020
Q2 		$766K Hold
56,454
– – ﹤0.01% 1679
2020
Q1 		$428K Buy
+56,454
New +$439K ﹤0.01% 1800

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans's AKBA Position: Q1 2021 in Review

Thrivent Financial for Lutherans sold out of Akebia Therapeutics (AKBA) in Q1 2021, closing a stake of 115,718 shares — an estimated $324K sold.

Thrivent Financial for Lutherans first reported a position in AKBA in Q1 2020 and held it in 4 quarters. The position peaked at $766K in Q2 2020. 145 funds tracked by Wall St. Rank hold AKBA as of Q1 2021.

  • Thrivent Financial for Lutherans reported no remaining Akebia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 115,718 Akebia Therapeutics shares in Q1 2021, an estimated $324K.
  • Thrivent Financial for Lutherans first reported a position in Akebia Therapeutics in Q1 2020 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Akebia Therapeutics position peaked at $766K in Q2 2020.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2021, filed 17 May 2021.